- Home
- BILL vs IONS Comparison
BILL vs IONS Comparison
Compare BILL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILL
- IONS
- Stock Information
- Founded
- BILL 2006
- IONS 1989
- Country
- BILL United States
- IONS United States
- Employees
- BILL N/A
- IONS N/A
- Industry
- BILL EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- BILL Technology
- IONS Health Care
- Exchange
- BILL Nasdaq
- IONS Nasdaq
- Market Cap
- BILL 5.9B
- IONS 6.0B
- IPO Year
- BILL 2019
- IONS 1991
- Fundamental
- Price
- BILL $45.72
- IONS $30.17
- Analyst Decision
- BILL Buy
- IONS Buy
- Analyst Count
- BILL 19
- IONS 19
- Target Price
- BILL $79.61
- IONS $59.24
- AVG Volume (30 Days)
- BILL 2.6M
- IONS 1.5M
- Earning Date
- BILL 05-01-2025
- IONS 05-06-2025
- Dividend Yield
- BILL N/A
- IONS N/A
- EPS Growth
- BILL N/A
- IONS N/A
- EPS
- BILL 0.39
- IONS N/A
- Revenue
- BILL $1,387,696,000.00
- IONS $705,138,000.00
- Revenue This Year
- BILL $15.80
- IONS N/A
- Revenue Next Year
- BILL $15.06
- IONS $25.71
- P/E Ratio
- BILL $117.57
- IONS N/A
- Revenue Growth
- BILL 16.42
- IONS N/A
- 52 Week Low
- BILL $42.82
- IONS $29.61
- 52 Week High
- BILL $100.19
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- BILL 33.37
- IONS 37.05
- Support Level
- BILL $46.69
- IONS $31.04
- Resistance Level
- BILL $51.57
- IONS $33.76
- Average True Range (ATR)
- BILL 2.08
- IONS 1.16
- MACD
- BILL 1.11
- IONS -0.30
- Stochastic Oscillator
- BILL 36.57
- IONS 10.92
About BILL BILL Holdings Inc.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.